- ISIN
- US09061G1013
- CUSIP
- 09061G101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 23, 1999
Highlights
- Market Cap
- $11.05B
- Enterprise Value
- $8.83B
- EPS (TTM)
- $1.37
- PE Ratio
- 40.76
- PEG Ratio
- 2.44
- Total Revenue (TTM)
- $3.24B
- Gross Profit (TTM)
- $2.46B
- EBITDA (TTM)
- $439.56M
- Year Range
- $49.26 - $66.28
- Target Price
- $89.92
- ROA (TTM)
- 3.13%
- ROE (TTM)
- 4.33%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BMRN Performance Chart
BioMarin Pharmaceutical Inc. (BMRN) is down 5.9% since the beginning of the year. At $56 per share, BMRN is trading 15.7% below its 52-week high of $66. Investors who bought $1,000 worth of BMRN shares 5 years ago would now be looking at an investment worth $677.
Loading charts...
Returns By Period
BioMarin Pharmaceutical Inc. (BMRN) has returned -5.94% so far this year and 1.64% over the past 12 months. Over the last ten years, BMRN has returned -3.15% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
BioMarin Pharmaceutical Inc.
- 1D
- 2.21%
- 1M
- 3.35%
- YTD
- -5.94%
- 6M
- -5.70%
- 1Y
- 1.64%
- 3Y*
- -15.76%
- 5Y*
- -7.51%
- 10Y*
- -3.15%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BMRN Monthly Returns History
Based on dividend-adjusted daily data since Jul 26, 1999, BMRN's average daily return is +0.07%, while the average monthly return is +1.34%. At this rate, an investment would double in approximately 4.3 years.
Historically, 55% of months were positive and 45% were negative. The best month was Feb 2000 with a return of +114.6%, while the worst month was Apr 2000 at -49.8%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, BMRN closed higher 49% of trading days. The best single day was Mar 20, 2000 with a return of +34.6%, while the worst single day was Aug 19, 2020 at -35.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.86% | 9.18% | -8.49% | -4.57% | 6.27% | -2.43% | -5.94% | ||||||
| 2025 | -3.61% | 12.31% | -0.66% | -9.90% | -8.82% | -5.34% | 5.24% | 0.73% | -7.05% | -1.09% | 4.41% | 6.26% | -9.58% |
| 2024 | -8.65% | -2.04% | 1.23% | -7.53% | -7.05% | 9.67% | 2.43% | 8.16% | -22.94% | -6.26% | 0.21% | -0.45% | -31.83% |
| 2023 | 11.46% | -13.66% | -2.36% | -1.23% | -9.48% | -0.30% | 1.44% | 3.92% | -3.17% | -7.95% | 11.82% | 5.86% | -6.83% |
| 2022 | 0.32% | -11.86% | -1.31% | 5.51% | -7.65% | 10.30% | 3.84% | 3.66% | -4.97% | 2.19% | 16.56% | 2.49% | 17.14% |
| 2021 | -5.60% | -6.46% | -2.48% | 3.19% | -0.80% | 7.94% | -8.04% | 9.75% | -8.22% | 2.51% | 8.91% | 2.39% | 0.75% |
Benchmark Metrics
BioMarin Pharmaceutical Inc. has an annualized alpha of 9.88%, beta of 0.98, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since July 26, 1999.
- This stock participated in 84.23% of S&P 500 Index downside but only 78.76% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 9.88%
- Beta
- 0.98
- R²
- 0.15
- Upside Capture
- 78.76%
- Downside Capture
- 84.23%
Return for Risk
Risk / Return Rank
BMRN ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BMRN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.98 | ||
| Sortino ratioReturn per unit of downside risk | -2.38 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.37 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | 0.07 | 2.78 | -2.71 |
| Martin ratioReturn relative to average drawdown | 0.15 | 12.44 | -12.29 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioMarin Pharmaceutical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioMarin Pharmaceutical Inc. was 90.58%, occurring on Aug 27, 2002. Recovery took 1350 trading sessions.
The current BioMarin Pharmaceutical Inc. drawdown is 62.52%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -90.58%Aug 2002 | 2y 5mo | 5y 4mo | 7y 10moMar 2000 - Jan 2008 |
Financial crisis2007–2009 | -74.89%Mar 2009 | 1y 23d | 3y 3mo | 4y 4moFeb 2008 - Jul 2012 |
2026 bear market2026 | -66.69%May 2026 | 10y 10mo | — | 10y 11moJul 2015 - now |
1999 bear market1999 | -37.97%Dec 1999 | 3mo 2d | 1mo 17d | 4mo 19dSep 1999 - Feb 2000 |
2014 bear market2014 | -33.02%Jul 2014 | 4mo 19d | 3mo 19d | 8mo 8dFeb 2014 - Nov 2014 |
Drawdown Indicators
| BMRN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.58% | -56.78% | -33.80% |
Max Drawdown (1Y)Largest decline over 1 year | -22.49% | -9.10% | -13.39% |
Max Drawdown (3Y)Largest decline over 3 years | -49.83% | -18.90% | -30.93% |
Max Drawdown (5Y)Largest decline over 5 years | -57.64% | -25.43% | -32.21% |
Max Drawdown (10Y)Largest decline over 10 years | -62.09% | -33.92% | -28.17% |
Current DrawdownCurrent decline from peak | -62.52% | -1.80% | -60.72% |
Average DrawdownAverage peak-to-trough decline | -45.53% | -10.71% | -34.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.15% | 2.03% | +9.12% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioMarin Pharmaceutical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioMarin Pharmaceutical Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BMRN, comparing it with other companies in the Biotechnology industry. Currently, BMRN has a P/E ratio of 40.8. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BMRN compared to other companies in the Biotechnology industry. BMRN currently has a PEG ratio of 2.4. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BMRN relative to other companies in the Biotechnology industry. Currently, BMRN has a P/S ratio of 3.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BMRN in comparison with other companies in the Biotechnology industry. Currently, BMRN has a P/B value of 1.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BMRN
Add BioMarin Pharmaceutical Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BMRN